Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390418 | 1.00 | KMT2A (0.56) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL13229651 | 0.88 | CTSK (0.59) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL8275379 | 0.88 | CTSS (0.59) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL24221821 | 0.86 | KMT2A (0.53) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL31517881 | 0.86 | KMT2A (0.56) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL6295388 | 0.84 | KMT2A (0.55) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL1022916 | 0.84 | KMT2A (0.55) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL25413150 | 0.84 | KMT2A (0.55) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL25413155 | 0.84 | KMT2A (0.55) | KMT2ACAPN1CTSKCTSSCA1 | |
| SCHEMBL13612436 | 0.84 | KMT2A (0.55) | KMT2ACAPN1CTSKCTSSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-8993607-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2012-02-23 | — | — | US | disclosed |
| US-20100197749-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB | 2010-08-05 | — | — | US | disclosed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
| EP-1979332-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007083089-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | KMT2A 1103/4885CAPN1 749/4885CTSK 957/4885 |
| US-20100197749-A1 | CHEMICAL COMPOUNDS | EDF1, ECE1, EDNRA | KMT2A 2713/4885CAPN1 3243/4885CTSK 3115/4885 |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | MKI67, MCL1, TP53 | KMT2A 3148/4885CAPN1 3176/4885CTSK 1336/4885 |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | KMT2A 4634/4885CAPN1 3365/4885CTSK 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.